Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | SER | Stock Option (right to buy) | Mar 26, 2024 | Common Stock | 24.4K | $0.06 | Direct | F1, F2 | ||||||
holding | SER | Stock Option (right to buy) | Mar 26, 2024 | Common Stock | 44K | $0.06 | Direct | F1, F2 | ||||||
holding | SER | Stock Option (right to buy) | Mar 26, 2024 | Common Stock | 48.8K | $0.06 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | Shares of capital stock of the corporation then known as Serina Therapeutics, Inc. ("Serina AL") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of August 29, 2023, by and among the Issuer, Canaria Transaction Corporation and Serina AL (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of capital stock was exchanged for 0.97682654 shares of the Issuer's common stock, giving effect to a reverse split of the Issuer's common stock of 1-for-35.17. |
F2 | The stock options are fully vested. |